Latest news
The first publication of the SGLT2 HYPE project is now available in the European Heart Journal (CardioPulse)!
The article presents the scientific rationale and trial design of SGLT2 HYPE — the first large-scale, randomized, outcome-driven trial investigating SGLT2 inhibition as a novel therapeutic strategy for hypertension. The project aims to generate robust evidence on cardiovascular and renal protection beyond blood pressure lowering and to help shape future hypertension care across Europe.
Patient Perspectives in the Development of the SGLT2 HYPE Home Blood Pressure App
Explore patient perspectives on the SGLT2 HYPE home blood pressure app supporting hypertension monitoring and patient engagement
SGLT2 HYPE Holds Its 2nd General Assembly Meeting in Hamburg
SGLT2 HYPE partners gathered in Hamburg for the 2nd General Assembly Meeting to discuss progress, collaboration, and next project steps
New EU-funded Project Aims to Transform Hypertension Treatment
SGLT2 HYPE is a guideline-relevant clinical trial aiming to establish SGLT2 inhibitors as a new standard in high blood pressure therapy, ultimately addressing one of the leading causes of premature mortality in Europe
Kick-Off meeting
SGLT2 HYPE Kicks Off with Momentum: A New Chapter in Hypertension Research Begins